GenSight Biologics Reports Interim Financial Results for the First Half of 2020 and Provides Operational Update

Regulatory News:

GenSight Biologics (Paris:SIGHT) (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma company focused on discovering and developing innovative gene therapies for retinal neurodegenerative diseases and central nervous system disorders, today reported its interim financial results for the first half of 2020 and provided recent operational updates. The full interim financial report is available on the Company’s website in the Investors section. The 2020 half-year financial statements were subject to a limited review by the Company’s statutory auditors and approved by the Board of Directors on July 29, 2020.

“Even as we push towards the final steps for filing the LUMEVOQ Marketing Authorisation Application with the European Medicines Agency in September, we are also laying the groundwork for fast and effective commercialization,” commented Bernard Gilly, co-founder and Chief Executive Officer of GenSight Biologics. “We are ready and able to continue the hard work to prepare for LUMEVOQ’s launch.”

2020 Half-Year Financial Results

In million euros		H1 2019		H1 2020
Operating income		2.5		3.3
Research and development expenses		(16.1)		(12.0)
Sales and marketing expenses		(0.4)		(0.9)
General and administrative expenses		(3.1)		(4.0)
Operating profit (loss)		(17.2)		(13.6)
Net income (loss)		(17.3)		(14.1)
EPS (in € per share)		(0.63)